HHV-6 Treatment News: Endo Approved for Generic Valcyte

http://www.empr.com/endo-approved-for-generic-valcyte/article/382267/

Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.

http://www.ncbi.nlm.nih.gov/pubmed/17276366

 

Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.

 Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies. Longer valganciclovir treatment correlated with an improved response. 

http://www.ncbi.nlm.nih.gov/pubmed/23080504